Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Express Scripts
Johnson and Johnson
Dow
Mallinckrodt

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,803,840

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,803,840
Title:Utilization of dialkylfumarates
Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
Inventor(s): Joshi; Rajendra Kumar (Zurich, CH), Strebel; Hans-Peter (Muri, CH)
Assignee: Biogen Idec International GmbH (Zug, CH)
Application Number:12/405,661
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,803,840
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 7,803,840

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 RX Yes No   Start Trial   Start Trial METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS   Start Trial
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 RX Yes Yes   Start Trial   Start Trial METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,803,840

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany198 53 487Nov 19, 1998

International Family Members for US Patent 7,803,840

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 242633   Start Trial
Australia 1157200   Start Trial
Australia 752733   Start Trial
Bulgaria 105396   Start Trial
Bulgaria 64837   Start Trial
Brazil 9914606   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Moodys
Colorcon
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.